Top 10 Companies Transforming the Companion Diagnostics Industry

Introduction

Overview of the Global Companion Diagnostics Industry

The global companion diagnostics industry connects therapeutic selection with measurable biomarkers detected through polymerase chain reaction, next-generation sequencing, immunohistochemistry, in-situ hybridization and liquid-biopsy platforms. A companion diagnostic supplies information considered essential for the safe and effective use of a corresponding medicine, including identifying patients likely to benefit or experience adverse reactions. The United States regulatory list contained approvals through June 12, 2026, covering biomarkers such as EGFR, HER2, BRAF, BRCA1, BRCA2, PD-L1, KRAS, RET, ESR1, FGFR, IDH1, IDH2 and homologous-recombination-repair genes. Oncology accounts for most commercial activity, although companion testing also supports treatments in hematology, infectious disease, gene therapy and rare disorders.

The industry has progressed from single-marker assays to comprehensive genomic profiling systems capable of analyzing hundreds of genes. Current examples range from QIAGEN’s 7-mutation KRAS assay and Abbott’s 5-variant IDH1 test to Illumina’s 517-gene panel and Tempus’ 648-gene tissue assay. Distributed testing systems allow hospitals and regional laboratories to retain samples locally, while centralized laboratory models provide specialist bioinformatics and quality control. The competitive structure includes diversified diagnostics corporations, sequencing manufacturers, molecular-testing laboratories and precision-oncology technology companies. This combination has created a mature regulated segment in the United States and Europe, alongside expanding adoption in Japan, Australia, South Korea, China, India, Saudi Arabia and the United Arab Emirates.

Market Evolution and Growth Drivers

The companion diagnostics industry began expanding commercially after targeted oncology medicines required biomarker-confirmed patient selection. FDA guidance issued in 2014 established development principles for in-vitro companion diagnostic devices, while subsequent guidance addressed group labeling for multiple oncology therapies in 2020. Regulatory expectations increasingly encourage drug and diagnostic developers to coordinate analytical validation, clinical validation, sample collection and approval timelines. In Europe, Regulation (EU) 2017/746 became applicable on May 26, 2022, placing companion diagnostics under notified-body conformity assessment and requiring consultation with a medicines authority. These frameworks have transformed companion testing from an optional laboratory service into a regulated component of therapeutic development and prescribing.

Technology improvements are accelerating adoption by increasing biomarker coverage while reducing tissue requirements and turnaround times. Thermo Fisher’s Oncomine Dx Express workflow can generate results in 1 day, while the Oncomine Dx Target Test covers 23 genes in the United States and 46 genes in certain international configurations. Guardant Health’s updated liquid-biopsy platform introduced in 2026 expanded its assessed genomic footprint by 100 times and can report results in as little as 7 days. Illumina’s distributed comprehensive profiling assay processes up to 7 patient samples with 2 controls per sequencing run. These measurable improvements support faster clinical decisions, broader laboratory participation and closer integration between pharmaceutical research, diagnostic development and routine oncology care.

Top 5 Latest Trends in the Companion Diagnostics Industry

1. Comprehensive genomic profiling and pan-cancer testing

2. Expansion of liquid-biopsy companion diagnostics

3. AI-enabled multiomic and digital pathology analysis

4. Decentralized companion testing in regional laboratories

5. Integrated drug-and-diagnostic co-development

Trend 1: Comprehensive Genomic Profiling and Pan-Cancer Testing

Comprehensive genomic profiling is replacing sequential single-gene testing when limited tumor tissue must be evaluated for multiple actionable alterations. Illumina’s TruSight Oncology Comprehensive analyzes 517 genes, RNA fusions involving 24 genes, 1 RNA splice variant and tumor mutational burden using formalin-fixed tissue. Tempus xT CDx evaluates alterations across 648 genes and reports microsatellite-instability status, while Thermo Fisher’s Oncomine portfolio combines DNA and RNA analysis for mutations, insertions, deletions, copy-number changes and gene fusions. Pan-cancer claims also allow one regulated platform to support multiple tumor types and targeted medicines. This trend reduces repeated tissue consumption and gives laboratories a scalable foundation for adding new companion diagnostic indications through supplemental regulatory submissions.

Trend 2: Expansion of Liquid-Biopsy Companion Diagnostics

Blood-based companion diagnostics are gaining importance when tissue is unavailable, unsafe to obtain or insufficient for molecular analysis. Guardant360 became the first FDA-approved comprehensive liquid-biopsy companion diagnostic, and its platform had accumulated 27 companion diagnostic indications globally by June 2026. The updated Guardant360 Liquid CDx integrates genomic and epigenomic information from a single blood draw, offers results in as little as 7 days and carries transferred indications covering lung, breast and colorectal cancers. Plasma testing also supports detection of resistance-associated biomarkers such as ESR1 mutations in advanced breast cancer and EGFR alterations in lung cancer. Negative plasma results may still require tissue confirmation because low circulating-tumor-DNA levels can reduce detection sensitivity.

Trend 3: AI-Enabled Multiomic and Digital Pathology Analysis

Artificial intelligence is moving companion diagnostics beyond isolated DNA variants by integrating genomic, epigenomic, transcriptomic, histological and clinical data. Guardant Health’s Smart Platform combines genomic and epigenomic signals with machine-learning models developed from data generated across over 1 million tested patients. Tempus has applied AI to precision medicine since its establishment in 2015 and has supported almost 1,500 research projects during its first 10 years. In tissue diagnostics, computational pathology can standardize tumor-cell identification, staining interpretation and biomarker scoring, particularly for PD-L1, HER2 and other immunohistochemistry-based assays. AI does not replace analytically validated thresholds, but it can improve workflow consistency, identify complex biomarker relationships and support patient-screening strategies for clinical trials.

Trend 4: Decentralized Companion Testing in Regional Laboratories

Distributed testing is allowing qualified hospitals and regional laboratories to perform regulated companion diagnostics without sending every specimen to a central reference facility. Thermo Fisher’s Oncomine Dx Target Test is approved or commercialized across 20 countries and covers over 550 million lives through public or private reimbursement arrangements. Illumina’s TruSight Oncology Comprehensive can be installed on the NextSeq 550Dx platform and processes up to 7 patient specimens per run, enabling healthcare systems to retain tissue and genomic data locally. QIAGEN is also developing distributable homologous-recombination-deficiency testing with Myriad Genetics. Decentralization can shorten logistics time, but each laboratory must maintain trained personnel, validated workflows, proficiency testing, instrument controls and region-specific regulatory compliance.

Trend 5: Integrated Drug-and-Diagnostic Co-Development

Drug-and-diagnostic co-development aligns biomarker discovery, assay validation and therapeutic trials before commercial launch. FDA guidance encourages coordinated development when treatment eligibility depends on a specific test, while the European Commission’s COMBINE pilot allows sponsors to test a medicinal product and companion diagnostic through a more harmonized application process. Thermo Fisher reports 16 pharmaceutical partners and 23 therapies associated with global Oncomine companion diagnostic labels. Agilent has tested over 1 million patients for PD-L1 expression through its diagnostic kits, reflecting the scale achieved through long-term pharmaceutical partnerships. Successful co-development requires synchronized sample strategies, predefined clinical cutoffs, manufacturing controls and regulatory submissions, reducing the risk that an approved medicine launches without an accessible validated test.

Top 10 Companies in the Companion Diagnostics Industry

The following 10 companies are not presented as a strict ranking. They were selected according to regulated product portfolios, technical capabilities, pharmaceutical partnerships, geographic reach, testing infrastructure and active participation in companion diagnostic development.

1. Abbott

Company Overview: Abbott traces its history to 1888 and employs 122,000 people serving patients in over 160 countries. Headquarters: Abbott Park, Illinois, United States. Core Companion Diagnostics Expertise: Abbott Molecular develops PCR and fluorescence-based assays for identifying treatment-relevant genomic alterations in hematologic and solid tumors. Major Products and Services: Abbott RealTime IDH1 detects 5 IDH1 R132 variants in blood or bone-marrow specimens, while Abbott RealTime IDH2 identifies 9 clinically relevant IDH2 variants. FDA companion diagnostic indications connect these assays with targeted treatments for acute myeloid leukemia and myelodysplastic syndromes. Abbott also supplies Vysis fluorescence in-situ hybridization probes and molecular instrumentation that support centralized oncology laboratories.

2. Agilent Technologies

Company Overview: Agilent was established as an independent company in 1999 and maintains approximately 18,000 employees with facilities, logistics operations and commercial activities across 110 countries. Headquarters: Santa Clara, California, United States. Core Companion Diagnostics Expertise: Its Dako-derived diagnostics business specializes in immunohistochemistry, pathology workflow standardization and pharmaceutical co-development. Major Products and Services: PD-L1 IHC 22C3 pharmDx supports treatment selection across multiple tumor types, while HER2, estrogen-receptor and other tissue assays operate on established pathology platforms. Agilent reports that over 1 million patients have been tested globally for PD-L1 expression using its diagnostic kits. FDA listings added new 22C3 indications for ovarian and gastroesophageal cancers during February 2026.

3. Guardant Health

Company Overview: Guardant Health was founded in 2012 and has developed precision-oncology testing across treatment selection, recurrence monitoring and early cancer detection. Headquarters: Palo Alto, California, United States. Core Companion Diagnostics Expertise: The company specializes in circulating-tumor-DNA analysis, liquid biopsy, epigenomic profiling, real-world evidence and AI-supported interpretation. Major Products and Services: Guardant360 CDx became the first FDA-approved comprehensive liquid-biopsy companion diagnostic, while the 2026 Guardant360 Liquid CDx expanded the genomic footprint by 100 times. The platform has generated evidence from over 1 million tested patients, delivers results in as little as 7 days and had 27 global companion diagnostic indications by June 2026, including EGFR, HER2, BRAF and ESR1 applications.

4. Illumina

Company Overview: Illumina was founded in 1998 and employs approximately 8,600 people across sequencing, informatics, clinical genomics and research markets. Headquarters: San Diego, California, United States. Core Companion Diagnostics Expertise: Illumina develops distributable next-generation sequencing instruments, reagents, analysis software and regulated comprehensive genomic profiling assays. Major Products and Services: TruSight Oncology Comprehensive evaluates 517 genes, fusions in 24 genes, 1 RNA splice variant and tumor mutational burden. The workflow requires 40 nanograms each of DNA and RNA, processes up to 7 patient specimens per run and produces results within 4–5 days. Its FDA companion diagnostic claims include NTRK fusions in solid tumors and RET fusions in non-small-cell lung cancer.

5. Invivoscribe

Company Overview: Invivoscribe has operated in precision diagnostics since 1995 and supports over 700 clinical and research laboratories across 160 countries. Headquarters: San Diego, California, United States. Core Companion Diagnostics Expertise: The company integrates assay development, clinical-trial testing, regulatory strategy, ISO 13485-controlled design, cGMP manufacturing and bioinformatics for hematologic malignancies. Major Products and Services: The LeukoStrat CDx FLT3 Mutation Assay detects internal tandem duplications and tyrosine-kinase-domain mutations associated with acute myeloid leukemia. Its analytical software applies a mutant-to-wild-type signal-ratio cutoff of 0.05. Invivoscribe also operates accredited laboratory capabilities in the United States, Germany, Japan and China and supplies clonality, minimal-residual-disease and NGS testing services.

6. Myriad Genetics

Company Overview: Myriad Genetics was founded in May 1991 and has built more than 3 decades of experience in hereditary cancer, tumor profiling and precision medicine. Headquarters: Salt Lake City, Utah, United States. Core Companion Diagnostics Expertise: Myriad focuses on BRCA1, BRCA2 and homologous-recombination-deficiency testing linked with PARP-inhibitor treatment decisions. Major Products and Services: MyChoice CDx analyzes BRCA1/2 sequence variants, insertions, deletions and large rearrangements while calculating a genomic-instability score from loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions. An FDA approval issued in March 2026 expanded its role as a companion diagnostic for niraparib in ovarian cancer, where HRD-positive tumors occur in close to 50% of advanced cases.

7. QIAGEN

Company Overview: QIAGEN was founded in 1984 and operates 35 subsidiaries across over 25 countries, supported by distribution in over 60 countries and approximately 5,700 employees. Headquarters: Venlo, Netherlands. Core Companion Diagnostics Expertise: QIAGEN develops sample-preparation technologies, real-time PCR assays, digital PCR, NGS workflows and bioinformatics for biomarker-guided treatment. Major Products and Services: The therascreen portfolio includes companion diagnostics for EGFR, KRAS, BRAF, PIK3CA, FGFR and PDGFRA alterations. Its KRAS RGQ PCR Kit detects 7 KRAS mutations, while the PDGFRA assay identifies the D842V mutation in gastrointestinal stromal tumors. QIAGEN had secured 10 FDA-approved PCR-based companion diagnostic indications by 2021 and has continued adding therapy-linked claims.

8. Roche

Company Overview: Roche was founded in Basel in 1896 and now employs over 100,000 people while supplying medicines and diagnostics in over 100 countries. Headquarters: Basel, Switzerland. Core Companion Diagnostics Expertise: Roche combines pharmaceutical development, tissue diagnostics, immunohistochemistry, in-situ hybridization, PCR and comprehensive genomic profiling within one corporate group. Major Products and Services: The VENTANA portfolio includes HER2, PD-L1, ALK and PTEN assays used with targeted therapies and immunotherapies. FDA actions during 2026 included companion indications for the VENTANA PTEN SP218 RxDx Assay, PATHWAY anti-HER2 4B5 antibody and VENTANA HER2 Dual ISH DNA Probe Cocktail. Roche’s integrated structure supports coordinated biomarker discovery, therapeutic trials, regulatory submissions and global assay commercialization.

9. Tempus AI

Company Overview: Tempus was founded in August 2015 and supported almost 1,500 research projects during its first 10 years. Headquarters: Chicago, Illinois, United States, where the company leases approximately 217,000 square feet of laboratory and office space. Core Companion Diagnostics Expertise: Tempus combines clinical sequencing, machine learning, multimodal healthcare data and pharmaceutical research services. Major Products and Services: xT CDx is an FDA-authorized 648-gene tissue-based assay that detects single- and multi-nucleotide variants, insertions, deletions and microsatellite-instability status. Its companion diagnostic claims include RAS-based treatment selection in colorectal cancer. A tumor-only version received FDA approval in 2026, supporting migration toward a unified regulated solid-tumor testing workflow.

10. Thermo Fisher Scientific

Company Overview: Thermo Fisher Scientific was formed through a 2006 merger and operates from a global headquarters in Waltham, Massachusetts. Its United States and Canadian operations include over 26,000 employees across more than 400 offices, manufacturing facilities and distribution locations. Core Companion Diagnostics Expertise: The company provides Ion Torrent sequencing, PCR technologies, automated sample-to-answer systems, regulated assay development and global pharmaceutical partnerships. Major Products and Services: The Oncomine Dx Target Test became the first distributable NGS companion diagnostic in 2017. Current configurations analyze 23 genes in the United States and 46 genes in selected international markets. The portfolio has 11 approved biomarker categories, 16 pharmaceutical partners and commercial activity across 20 countries.

Regional Outlook

North America

North America has the most established commercial environment for companion diagnostics because the United States links FDA-authorized tests directly with therapeutic labeling. The regulatory list was updated in 2026 with new indications for plasma, tissue, immunohistochemistry and sequencing tests involving colorectal, breast, ovarian, prostate and lung cancers. Medicare’s National Coverage Determination 90.2 provides a national pathway for qualifying next-generation sequencing tests used in somatic and germline cancer. Research infrastructure also remains influential: the NCI-MATCH trial screened 6,000 patients using a 143-gene panel, and 62.5% of those patients had tumors outside the 4 most common cancer categories.

Canada added a national genomics strategy in February 2025 with a 7-year implementation horizon focused on commercialization, data coordination, personalized medicine and workforce development. The United States remains the primary location for companion diagnostic headquarters, FDA submissions and pharmaceutical co-development, while Canada contributes genomic research networks and publicly coordinated healthcare adoption. Mexico offers a large clinical-testing market but faces differences in laboratory accreditation, reimbursement and access between major urban hospitals and regional facilities. Across the 3 countries, future adoption depends on reducing test-result delays, expanding biomarker testing outside academic centers and ensuring that approved targeted medicines are paired with locally accessible diagnostics rather than tests available only through distant reference laboratories.

Europe

Europe’s companion diagnostics framework changed materially when Regulation (EU) 2017/746 became applicable on May 26, 2022. The regulation classifies companion diagnostics under a risk-based system, requires notified-body conformity assessment and introduces consultation with a medicines authority regarding biomarker suitability. These requirements apply across 27 European Union member states, creating a common regulatory foundation but also increasing documentation, clinical-evidence and post-market-surveillance obligations. From May 28, 2026, use of the first 4 EUDAMED modules became mandatory, covering actor registration, device registration, notified bodies and certificates, and market-surveillance functions. These systems improve traceability but can extend preparation timelines for smaller diagnostic developers.

Germany, France, Italy, Spain, the Netherlands and Nordic countries support distributed pathology and molecular-testing networks, while the United Kingdom operates through its separate medicines and device framework. The United Kingdom plans for Genomics England to hold over 500,000 genomes by 2030, building on the 100,000 Genomes Project and NHS genomic services. The NHS also carried out over 340,000 rare-disease genomic tests in 2025, demonstrating the scale of its laboratory and informatics infrastructure. European opportunities include harmonized clinical evidence and cross-border testing, whereas challenges include notified-body capacity, differences in reimbursement and the need to transition legacy assays into fully compliant IVDR products.

Asia-Pacific

Asia-Pacific combines large cancer populations with expanding domestic sequencing, pathology and pharmaceutical industries. Japan has promoted whole-genome analysis through an action plan initiated in 2019 and a subsequent implementation period covering approximately 5 years from fiscal 2022. Japan also uses locally approved companion diagnostics for biomarkers such as EGFR, ALK, BRAF, HER2, MET, RET and ROS1. Thermo Fisher’s Oncomine companion diagnostic network includes Japan, South Korea and Australia among its 20 listed countries, while multinational manufacturers maintain application, training and service operations in China, India, Singapore and Taiwan. These systems support broader local testing but still require country-specific validation, registration and reimbursement strategies.

Australia established Genomics Australia on July 1, 2025, creating a national body to coordinate genomic technologies, research and clinical implementation. National programs also support precision-oncology screening and clinical-trial matching. China maintains extensive sequencing and diagnostic manufacturing capacity but requires local regulatory submissions, population-specific validation and secure handling of genomic data. India offers a rapidly developing molecular-diagnostics workforce, with companies such as Agilent employing over 1,500 people across 9 Indian locations. Asia-Pacific growth opportunities therefore center on localized manufacturing, distributed hospital testing and biopharma partnerships, while major risks include uneven laboratory quality, shortages of molecular pathologists and differing rules for sample transfer, cybersecurity and genetic-data governance.

Middle East and Africa

The Middle East is developing genomic infrastructure through national transformation strategies. Saudi Arabia launched its National Biotechnology Strategy in January 2024 with targets extending to 2040 and plans for 11,000 specialized biotechnology jobs by 2030. King Faisal Specialist Hospital reported a 67% reduction in whole-genome-sequencing cost and a fivefold increase in analytical capacity, with an objective of expanding testing access by 2030. The United Arab Emirates introduced a 10-year National Genome Strategy in 2023, supported by the Emirati Genome Programme, artificial intelligence and population-specific genomic reference data. These initiatives can attract companion diagnostic trials and localized testing partnerships, provided regulatory, reimbursement and workforce systems develop at comparable speed.

Africa’s companion diagnostic adoption remains concentrated in selected academic hospitals, private laboratories and research centers in South Africa, Egypt, Kenya, Nigeria, Morocco and Namibia. African populations represented only 1.1% of global genomic data in 2021, limiting the validation of biomarkers and algorithms across genetically diverse populations. Namibia recorded about 4,000 new cancer cases annually and hosted its first international cancer genomics conference in September 2025. Local diagnostic manufacturing is also advancing: a Nigerian company received a technology sublicense in 2025 to produce rapid tests initially focused on 3 infectious-disease targets. Companion diagnostics will require additional sequencing infrastructure, oncology access, biobanks, trained bioinformaticians and regionally representative clinical evidence.

Future Opportunities in the Companion Diagnostics Industry

Future opportunities will center on multiomic assays capable of combining DNA mutations, RNA expression, methylation, proteins and digital pathology within 1 clinically validated workflow. Liquid biopsy can expand treatment selection where tissue collection is difficult, while AI can support variant prioritization, quality control and trial matching. Broader group labeling may allow one companion diagnostic to support multiple therapies targeting the same biomarker, reducing duplicated development. Distributed systems with 1-day or 4–5-day turnaround times can bring testing closer to regional hospitals. However, analytical expectations will remain strict: developers must demonstrate sensitivity, specificity, reproducibility, sample stability and performance at clinically defined decision thresholds before algorithms or multiomic signatures can guide prescribing.

Geographic expansion also creates opportunities for local manufacturing, technology transfer and regional reference laboratories. Saudi Arabia’s 2030 workforce target, the United Kingdom’s 500,000-genome objective and Australia’s national genomics coordination illustrate verified infrastructure commitments that can support future companion diagnostic adoption. Analytical expectations include stronger participation from small and medium-sized diagnostic companies through pharmaceutical partnerships, cloud-based regulatory documentation and standardized assay-development platforms. Expansion into autoimmune disease, neurological disorders, rare diseases and gene therapy is plausible where treatment eligibility depends on measurable biomarkers. These opportunities remain analytical expectations rather than guaranteed outcomes, and commercial success will depend on regulatory alignment, medicine availability, clinician education and equitable testing access.

Conclusion

The Top Companies in the Companion Diagnostics Industry operate across a technically diverse ecosystem that includes PCR, immunohistochemistry, in-situ hybridization, next-generation sequencing, liquid biopsy and AI-enabled multiomic analysis. The 5 major trends—comprehensive profiling, liquid biopsy, AI integration, decentralized testing and coordinated co-development—are changing how laboratories identify patients for targeted treatments. The 10 selected companies contribute distinct capabilities, ranging from Abbott’s 5-variant IDH1 assay and QIAGEN’s 7-mutation KRAS test to Illumina’s 517-gene panel, Tempus’ 648-gene assay and Guardant Health’s blood-based platform with 27 global companion diagnostic indications.

Regional conditions remain uneven. North America combines FDA authorization, Medicare coverage and large precision-oncology trials; Europe operates under IVDR rules applicable since 2022; Asia-Pacific is developing domestic sequencing and regulated testing networks; and the Middle East and Africa are building genomic infrastructure through national strategies and laboratory investment. The strongest future opportunities involve faster distributed testing, broader biomarker coverage, representative genomic datasets, localized manufacturing and multiomic interpretation. Competitive advantage will increasingly depend on the ability to coordinate therapeutic trials, regulatory evidence, manufacturing quality, clinical software and global laboratory access within a single development program extending toward verified national targets in 2030 and 2040.